August 30, 2024

Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis

Key Points

Key points are not available for this paper at this time.

Abstract

In this retrospective cohort study, vedolizumab was associated with higher odds of steroid-free clinical remission at 1 year compared to anti-TNF agents for bio-naïve patients with ulcerative proctitis.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Rahul S. Dalal

Brigham and Women's Hospital

Lindsay Clarke

Brigham and Women's Hospital

Alex Carlin

Brigham and Women's Hospital

Journals

Inflammatory Bowel Diseases

Actions

Institutions

Harvard University

Brigham and Women's Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study